Interventional device developer Abbott Vascular Devices is readying a large U.S. trial of drug-eluting stents. The proposed 1,670-patient randomized clinical trial will compare Abbott's ZoMaxx drug-eluting stent with Boston Scientific's Taxus Express2 drug-eluting stent. It will be conducted at more than 70 centers in North America.
The stents will be compared with a primary end point of nine-month target vessel revascularization, according to the company, which is a division of Abbott Laboratories of Abbott Park, IL. Enrollment for the trial is expected to begin by the end of the year, and Abbott plans to have a product on the market in the U.S. by 2007.
By AuntMinnie.com staff writers
September 28, 2004
Related Reading
Abbott starts ZoMaxx stent trial, September 17, 2004
Abbott debuts StarClose, May 26, 2004
Abbott launches Perclose ProGlide, May 13, 2004
Abbott Labs launches endovascular unit, January 28, 2004
Abbott finishes Jomed deal, July 1, 2003
Copyright © 2004 AuntMinnie.com
